Articles related to Psychiatric Pharmacy (BCPP)

Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.

The FDA issued a Class II recall for an amphetamine-based ADHD medication after a labeling mix-up resulted in immediate-release capsules being packaged as extended release. The recall affects a single lot totaling 1,392 bottles.

A rapid review found that ADHD stimulant misuse declined in several recent US surveys, particularly among younger adults, although millions continued to report misuse. Evidence linked frequent misuse with polysubstance use, while long-term health consequences remain poorly characterized.

The FDA approved centanafadine for ADHD in adults and children aged 6 years and older, introducing the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for the disorder. Approval was based on phase 3 trial results and regulatory review.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

An observational study associated repeated gabapentin prescribing with higher rates of dementia and mild cognitive impairment, particularly among adults aged 18 to 64 years. Experts emphasized that the findings do not establish causality and should be interpreted cautiously.